-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On November 8, 2021, Alnylam Pharmaceuticals announced the initiation of a global phase 2 clinical trial to evaluate RNAi therapy zilebesiran (formerly ALN-AGT) in hypertensive patients whose blood pressure cannot be adequately controlled by standard antihypertensive drug therapy.
Hypertension is a complex multi-factor disease.
RNAi (RNA interference) is a natural cellular process of gene silencing, and the discovery of it won the 2006 Nobel Prize in Physiology or Medicine
Zilebesiran is an RNAi therapy targeting mRNA that expresses angiotensinogen
▲Zilebesiran's mechanism of action (picture source: Alnylam official website)
This randomized, double-blind, placebo-controlled Phase 2 clinical trial will enroll approximately 800 adult hypertensive patients who have previously received standard antihypertensive medications
Reference materials:
[1] Alnylam Initiates KARDIA-2 Phase 2 Study of Investigational Zilebesiran (ALN-AGT) in Patients with Inadequately Controlled Hypertension.